Full-Time
Genetic testing for rare disease diagnostics
$183.7k - $229.6k/yr
Senior
Remote in USA
Upload your resume to see how it matches 14 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
GeneDx specializes in genetic testing to diagnose rare diseases by analyzing patients' DNA for mutations linked to health conditions. The company collects DNA samples through cheek swabs, blood, or other specimens and sequences them to identify genetic variations. With over 300,000 clinical patient exomes sequenced, GeneDx provides rapid testing services, including products like GenomeXpress and XomeDx Xpress, which deliver results in as little as seven days. This quick turnaround is crucial for timely diagnoses that can improve treatment outcomes and reduce healthcare costs. Unlike competitors, GeneDx focuses on personalized medicine and offers digital Patient Letters to help patients and families understand their genetic information. The company's goal is to enhance the diagnosis and management of genetic conditions through accurate and efficient testing.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2000
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Employee Discounts
Voluntary benefits
GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category.
GeneDx Showcases Groundbreaking Genomic Research at 2025 ACMG Annual Clinical Genetics Meeting
GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights.
What You Should Know: – GeneDx, a leader in delivering improved health outcomes through genomic insights launches Multiscore, an advanced AI-powered decision support tool. – Multiscore is designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights.Advanced Decision Support System Enhances Diagnostic Efficiency Embedded into GeneDx’s interpretation platform, Multiscore acts as a decision support tool, helping clinical geneticists focus on the most relevant genes during their clinical analysis. This innovation will be presented at the ACMG (American College of Medical Genetics and Genomics) meeting in a session titled: “Multiscore, a Gene Ranker Powered by Artificial Intelligence and Real-World Clinical Data, Shows High Sensitivity in 10,000 Exomes and Genomes,” which was selected for a limited-spot industry-specific platform session.Leveraging AI and Extensive Data for Enhanced Gene RankingMultiscore utilizes a powerful combination of GeneDx’s industry-leading proprietary dataset, publicly available data, and advanced AI to prioritize genes in exome and genome sequences. This prioritization is based on how well the genes align with a patient’s clinical presentation. By incorporating phenotypic similarities into gene ranking criteria, GeneDx can better serve patients whose symptoms may deviate from textbook descriptions. This approach also facilitates the identification of pathogenic or likely pathogenic diagnoses in complex cases.Transforming Genetic Analysis with AIMultiscore’s ability to incorporate phenotypic similarities into gene ranking is particularly significant, as it addresses the challenge of diagnosing patients with atypical symptoms. This AI-driven approach ensures that even complex cases can be analyzed efficiently and accurately.By leveraging the power of AI and its vast database, GeneDx is empowering clinical geneticists to make more informed decisions, ultimately improving patient outcomes
GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA.